The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The trial also demonstrated significant improvements across multiple secondary endpoints
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Subscribe To Our Newsletter & Stay Updated
